3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week
One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases.
One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases.
While the selling that was reported this week was consistent with what we have seen so far in March, nothing indicates a mass exodus for shareholders at this point.
This past week's trading was marked with huge up and down swings and a rise and fall in volatility. Generally, this is the kind of market action that makes strategists nervous.
Deutsche Bank analysts focused on three companies that stand to benefit from the continued effort by the carriers to build out network capacity.
A new report from the Dividend Ruler analysts at UBS highlights the many stocks in the current portfolio that have already raised dividends this year.
RBC analysts focused on four stocks that could also see an impact from the recent decline in PC sales.
A new research note from Deutsche Bank focuses on some of the well-known, but lower profile Internet stocks that could be poised for big things.
Here are five stocks on the Merrill Lynch SMID-Cap Alpha list that have some big news and events that may be right around the corner. All are rated Buy at Merrill Lynch.
A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to outperform this year.
With solar companies supplying strong earnings reports and excitement over the newly created yieldco in the industry, it is easy to see why the RBC team is bullish.
In the wake of the Federal Reserve Dodd-Frank Act stress tests, Jefferies thinks these four banks will see the biggest increases in dividend yields.
A new report from Merrill Lynch takes a very long look at the S&P 500 and current market conditions. It makes a very solid case that investors should remain in the stock market.
A new research report from the Information Technology and Hardware analysts at UBS tracks the stocks that are the most overbought and oversold on a relative strength basis.
While not the least bit surprising, given the big advance over the past year, some insider sales this past week were pretty staggering in size.
One thing we have noticed as the market has crept steadily higher this year is that insider buying has never hit a wall.
A new research report from Credit Suisse spotlights good stocks on which very few analysts on Wall Street provide research.
From a massive list of stocks that are in the climate change and extreme weather theme at Merrill Lynch, we zeroed in on the firm's top alternative energy companies.
Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics acquisition.
The oil services trade is still a contrarian one, to say the least. The pain in the industry is not going away anytime soon, so sticking with the top names that weathered downturns before…
Here are five new members of the Credit Suisse Top Picks list in five separate market sectors. They look poised for a solid remainder of 2015.